首页> 外文期刊>Reproductive biomedicine online >Prospective assessment of follicular growth and the oocyte cohort after ovarian stimulation for fertility preservation in 90 cancer patients versus 180 matched controls
【24h】

Prospective assessment of follicular growth and the oocyte cohort after ovarian stimulation for fertility preservation in 90 cancer patients versus 180 matched controls

机译:卵泡生长的前瞻性评估卵巢刺激后90例癌症患者生育保存后的卵巢刺激率与180例匹配对照

获取原文
获取原文并翻译 | 示例
           

摘要

A lower number of metaphase II oocytes eligible for vitrification after controlled stimulation in cancer patients has recently been reported, suggesting that cancer may impair the dynamics and quality of follicular growth. In this prospective, non-interventional study, the pattern of follicular growth and oocyte cohort after ovarian stimulation in cancer patients was analysed. Ninety cancer patients, recruited before starting chemotherapy, were compared with 180 time-and age-matched healthy controls undergoing intracytoplasmic sperm injection. Primary outcome was total number of metaphase II oocytes and metaphase II/total oocytes rate. Basal anti-Mullerian hormone levels (P 0.05) and antral follicle count (P 0.0001) were significantly lower in cancer patients. Recombinant FSH total dose was significantly higher in the cancer group (P 0.0001). No differences were found in duration of stimulation, mean number of mature follicles on day of ovulation induction and total oocyte number after retrieval; the number of metaphase II oocytes retrieved (6.2 +/- 4.7 versus 8.8 +/- 4.2; P 0.0001) and number of metaphase II oocytes-total oocytes ratio were significantly lower in cancer patients (56% versus 78%, P 0.0001). Fewer metaphase II oocytes were eligible for vitrification and lower maturation rate in the cancer group. (C) 2018 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
机译:据报道,患有癌症患者的受控刺激后有资格进行玻璃化的较少数量的中期II卵母细胞,表明癌症可能会损害卵泡生长的动态和质量。在这种前瞻性,非介入研究中,分析了癌症患者卵巢刺激后卵泡生长和卵母细胞队列的模式。在开始化疗之前募集的九十癌症患者与接受血管科上质精子注射的180次和年龄匹配的健康对照进行比较。主要结果是中期卵母细胞的总数和中期II /总卵母细胞率。基底抗Mullerian激素水平(P <0.05)和癌症患者的嗜睡卵泡计数(P&LT; 0.0001)显着降低。在癌症组中重组FSH总剂量显着较高(P <0.0001)。在刺激持续时间内没有发现差异,在排卵诱导日的成熟卵泡的平均数量和检索后的总卵母数;所检索的中期II卵母细胞的数量(6.2 +/- 4.7与8.8 +/- 4.2; p& 0.0001)和癌症患者的中期卵母细胞总卵母细胞的数量显着降低(56%对78%,p&lt ; 0.0001)。较少的中期II卵母细胞有资格获得癌组中的玻璃化和较低的成熟率。 (c)2018年Elsevier Ltd.出版的Everyver Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号